Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology

Capricor Therapeutics announced that its HOPE-3 Phase 3 trial results for Deramiocel in Duchenne muscular dystrophy received the American Heart Association's Outstanding Research Award in Pediatric Cardiology. The cardiac data showed that Deramiocel improved left ventricular ejection fraction by 2.8 percentage points in cardiomyopathy patients (p=0.02) and reduced new heart scarring by 2.9 segments compared to natural history controls (p=0.01). The company's Biologics License Application remains under FDA review with a PDUFA target action date of November 22, 2026.